NCT00428584 - RNF and Betaseron® Tolerability Study | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

September 30, 2009

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

DRUG

New Formulation of rebif - human interferon beta-1a

New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.

DRUG

Interferon beta -1b

Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.

Trial Locations (1)

EMD Serono Med Info, Rockland